Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EPS (Weighted Average and Diluted) (2021 - 2025)

Cue Biopharma's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.07 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 58.82% year-over-year to -$0.07; the TTM value through Sep 2025 reached -$0.41, up 54.95%, while the annual FY2024 figure was -$0.72, 35.14% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.07 at Cue Biopharma, roughly flat from -$0.07 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.07 in Q2 2025 and bottomed at -$0.44 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.25 (2021), against an average of -$0.25.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 48.0% in 2022 before it skyrocketed 65.52% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.25 in 2021, then plummeted by 48.0% to -$0.37 in 2022, then rose by 21.62% to -$0.29 in 2023, then soared by 65.52% to -$0.1 in 2024, then rose by 30.0% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for CUE's EPS (Weighted Average and Diluted) are -$0.07 (Q3 2025), -$0.07 (Q2 2025), and -$0.17 (Q1 2025).